Lycke M
No ORCID on file
· 6 papers in corpus
· active 2020-2025
Top journals
Frequent coauthors
- Sundfeldt K 5
- Enroth S 3
- Gyllensten U 3
- Ivansson E 3
- Karin Stålberg 3
- Hedlund Lindberg J 3
- Benitez J 3
- Cook LS 2
- Brand AH 2
- Carney ME 2
2025
BackgroundOvarian cancer has the highest mortality of all gynecological cancers and surgery is commonly used as final diagnostic. Available literature indicates that women with benign tumors could often be conservatively managed, but accura…
2025
ObjectiveMany epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unk…
2023
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carci…
2022
BackgroundOvarian cancer is the eighth most common cancer among women and due to late detection prognosis is poor with an overall 5-year survival of 30-50%. Novel biomarkers are needed to reduce diagnostic surgery and enable detection of ea…
2022
Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer.
BackgroundOvarian cancer is the eighth most common cancer among women and has a 5-year survival of only 30-50%. The survival is close to 90% for patients in stage I but only 20% for patients in stage IV. The presently available biomarkers h…
2020
Ovarian cancer is the most lethal gynecologic cancer. Pre-diagnostic testing lacks sensitivity and specificity, and surgery is often the only way to secure the diagnosis. Exploring new biomarkers is of great importance, but the rationale of…